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Protein acetylation, which is central to transcriptional control as well as other cellular processes, is disrupted in
Huntington’s disease (HD). Treatments that restore global acetylation levels, such as inhibiting histone deacety-
lases (HDACs), are effective in suppressing HD pathology in model organisms. However, agents that selectively
target the disease-relevant HDACs have not been available. SirT1 (Sir2 inDrosophilamelanogaster) deacetylates
histones and other proteins including transcription factors. Genetically reducing, but not eliminating, Sir2 has
been shown to suppress HD pathology in model organisms. To date, small molecule inhibitors of sirtuins have
exhibited low potency and unattractive pharmacological and biopharmaceutical properties. Here, we show that
highly selective pharmacological inhibitionofDrosophilaSir2and mammalian SirT1 using the novel inhibitor seli-
sistat (selisistat;6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide)cansuppressHDpathologycausedby
mutanthuntingtinexon1fragments inDrosophila,mammaliancellsandmice.WehavevalidatedSir2asthe invivo
target of selisistat by showing that genetic elimination of Sir2 eradicates the effect of this inhibitor in Drosophila.
The specificity of selisistat is shown by its effect on recombinant sirtuins in mammalian cells. Reduction of HD
pathology by selisistat in Drosophila, mammalian cells and mouse models of HD suggests that this inhibitor
has potential as an effective therapeutic treatment for human disease and may also serve as a tool to better under-
stand the downstream pathways of SirT1/Sir2 that may be critical for HD.
INTRODUCTION
Huntington’s disease (HD) is a progressive neurodegenerative
disease, caused by an expanded CAG repeat in the HD gene on
chromosome 4. This mutation produces an extended N-terminal
polyglutamine stretch in the huntingtin (Htt) protein and results
in progressive clinical symptoms and neuronal cell death.
This process is accompanied by significant transcriptional
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dysregulation and reduced chromatin acetylation (1–3). Genetic
manipulations that influence histone acetylation such as reduc-
tion of histone deacetylases (HDACs) can restore mutant Htt
(mHtt)-challenged cells, flies and mice toward their predisease
state (4–6).
Three classes of HDACs can be defined based on their
homology to yeast proteins and co-factor requirements (7) with
homologs of the yeast silent information regulator 2 (Sir2)
being unique among HDACs in that they employ nicotinamide
adenine dinucleotide (NAD+) as a cofactor and comprise the
Class III HDACs (8). Genetic and pharmacologic studies with a
Drosophila model of HD suggest that partial reduction (but not
complete deletion) of Sir2 is protective in animals challenged
with mHtt exon 1 fragments (9). In addition, genetic manipula-
tions found reduced SirT1/Sir2 to be beneficial in other neurode-
generative models, such as oxidatively challenged neurons (10)
and a Drosophila model expressing mutant Ataxin-3 (11).
Further, in transgenic mice, Alzheimer’s disease pathology was
improved by treating mice with the non-selective sirtuin inhibitor
nicotinamide (12). These observations suggest that pharmaco-
logical inhibition of Sir2 may be effective for the treatment of
HD and possibly other diseases. Accordingly, we sought to test
the efficacy of pharmacologic inhibition of SirT1 in multiple pre-
clinical models of HD. Unfortunately, drug-like and highly select-
ive inhibitors of SirT1 with good biopharmaceutical properties
have been few. Nicotinamide acts as a competitive inhibitor by
binding SirT1 to regenerate NAD+ and reduce SirT1 deacetylase
activity (13–15), but presumably has a similar effect on all other
NAD+ requiring sirtuins. Sirtinol inhibits SirT1 with an IC50 of
131 mM and SirT2 with an IC50 of 40 mM (16,17). Other inhibitors,
including guttiferone G, hyperforin and aristoforin, inhibit both
SirT1 and SirT2 in the low-micromolar range (18). A recently
described set of indole-based molecules exhibits a 500-fold
improvement over previously described SirT1 inhibitors and
exhibits promising biopharmaceutical properties with a high
degree of specificity and selectivity towards SirT1 as opposed to
other sirtuins (14,19,20). Here we report that the highly specific
SirT1/Sir2 inhibitor selisistat (selisistat; SEN0014196, EX-527,
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; CAS
RN 49843-98-3) is effective in suppressing HD pathology in
Drosophila, mammalian cells and mouse models. We report
target validation studies demonstrating that the in vivo target
responsible for these effects is indeed SirT1/Sir2. We also show
thatactivityofboth DrosophilaSir2andhuman SirT1 is decreased
by treatment of transfected cells with selisistat. Selisistat is
currently in clinical trials in HD patients and has proven to be
safe and well tolerated in healthy human volunteers, potentially
making this drug an exciting option for SirT1-lowering regimens
in humans that may be effective in treating HD and possibly other
diseases.
RESULTS
Genetic or pharmacological inhibition of Sir2/SirT1 is
protective in a Drosophila HD model
To determine if deacetylation activity driven by Sir2 mitigates
neurodegeneration, we tested whether the pathology observed
in transgenic Drosophila expressing an expanded mutant
human Htt exon 1 fragment in all neurons is affected when the
animals are homozygous or heterozygous for a null mutation
of Sir2. We measured both morphological loss of photoreceptor
neurons (Fig. 1A) and physiological loss of motor function
(Fig. 1B). The compound eye of Drosophila contains1000 om-
matidia each containing eight retinal neurons (photoreceptor
cells). Seven of these can be detected by visualizing rhabdo-
meres (the light gathering organ of each photoreceptor neuron)
with the pseudopupil technique (6,21). Animals expressing
mHtt (Httex1pQ93) pan neuronally exhibit loss of retinal
neurons. When Htt-expressing animals are also heterozygous
for a mutation of the Sir2 (+/2), the extent of neuronal loss is
reduced (Fig. 1A). However, animals with no functioning Sir2
(2/2) show more neuronal loss than siblings with two function-
ing copies (Fig. 1A). Similarly, Htt-challenged animals hetero-
zygous for Sir2 (+/2) show improved motor function
compared to siblings with normal Sir2 (+/+) levels. In contrast,
complete loss of Sir 2 (2/2) severely compromises climbing
ability (Fig. 1B). Thus, genetic loss of a single copy of Sir2 alle-
viates pathology by both measures while loss of both copies of
Sir2 exhibits reduced rescue compared with Sir2 heterozygotes
(Fig. 1AB).
Treatmentwith selisistat rescues neuronal degeneration and
extends lifespan in Htt-challenged Drosophila
Genetic reduction of Sir2 levels points to Sir2 as an attractive
target for pharmacologic intervention. Accordingly, we tested
whether pharmacologic suppression of Sir2 by selisistat would
be effective in suppressing mHtt-mediated pathology in vivo
using our Drosophila model of HD. Adult flies expressing
mHtt exon 1 were placed on food containing 0.1, 1 or 10 mM seli-
sistat on the first day after eclosion (i.e. emergence as an adult). In
untreated animals, neurodegeneration as measured by photo-
receptor neuron survival (22) gets progressively worse until
death on or about Day 7 posteclosion. Sibling animals treated
with selisistat show a concentration-dependent rescue of photo-
receptor neurons (Fig. 1C). At 10 mM, selisistat is able to rescue
degeneration to at least the same level as genetic loss of one copy
of the Sir2 gene (Supplementary Material, Fig. S1). These results
show that treatment with selisistat rescues neurodegeneration in
a Drosophila model of HD and that the rescue is at least as robust
as the maximum rescue achieved genetically.
To determine whether selisistat also affects the early death
phenotype caused by expressing mHtt (Httex1pQ93) with a pan-
neuronal driver (9), wemonitored the lifespan of mHtt-challenged
flies treated with 0 and 10 mM selisistat. Treatment with 10 mM
selisistat tends to extend the lifespan of mHtt-challenged
animals compared to untreated flies with the greatest effect seen
in the 10–20 day survival (P, 0.01) (Fig. 1D). These effects
are not due to modulation of mHtt transgene expression in the
animals, as transgene mRNA levels are not altered in treated
flies (Supplementary Material, Fig. S2).
Sir2 is the in vivo target of selisistat activity in Drosophila
To further assess whether Sir2 is the in vivo target of selisistat in
Drosophila, we compared the ability of selisistat to rescue neu-
rodegeneration in HD animals with a normal Sir2 gene dosage
compared to its ability to rescue siblings homozygous for a
null allele of Sir2. If Sir2 is really the in vivo target of selisistat,
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absence of any functioning Sir2 gene should abolish the ability
of selisistat to improve pathology. Results show that mHtt-
challenged flies with two normal copies of Sir2 show an
40% recovery of retinal neurons when treated with 10 mM seli-
sistat (Fig 2A). However, when sibling HD flies homozygous for
a null allele of Sir2 are treated with different concentrations of
selisistat, no significant change in photoreceptor degeneration
is observed when compared with untreated flies even with
10 mM selisistat (Fig. 2A). Similarly, mHtt-challenged animals
with a normal (double) dose of Sir2 show improved motor func-
tion when fed up to 10 mM selisistat (Fig. 2B). However, the re-
sponse to selisistat is completely abolished in mHtt-challenged
animals that are also homozygous null for Sir2 (2/2). These
results suggest that selisistat not only inhibits Sir2 in vitro, but
that the beneficial effects of selisistat in vivo are completely
dependent on the presence of functioning Sir2.
Selisistat specificity in mammalian cells
To determine the specificity and activity of selisistat on sirtuins,
HEK293 cells were transfected with GCN5 (a histone
acetyltransferase), and the nuclear factor kappa B (NFkB) p65
subunit (a characterized SirT1 substrate) (23). GCN5 actively
acetylates p65 as indicated by the ratio of acetylated p65 to total
p65 protein in transfected cells (Fig. 3A, B, D and E). When
human SirT1 is also co-transfected along with GCN5 and p65,
the level of p65 acetylation is reduced by 80% (Fig. 3A and
B). When Drosophila Sir2 is co-transfected into cells, the GCN5
acetylation of p65 is reduced by 70% (Fig. 3D and E). The add-
ition of selisistat to these cells suppresses the SirT1 deacetylation
restoring 50% of the p65 acetylation at 10 mM (Fig. 3A and C).
Similarly, selisistat blocks the ability of Drosophila Sir2 to deace-
tylate p65 as indicated by the 60% recovery of the inhibited acetyl-
ation activity (Fig. 3D and F). These data show that selisistat
inhibits the deacetylation activity of both Drosophila Sir2 as
well as human SirT1.
Selisistat is protective in cultured mammalian cell models of
HD
Given the robust positive effects of genetically reducing Sir2 on
HD pathology in Drosophila, we sought to determine whether
Figure 1.Genetic and pharmacologic modulation of Sir2 affects mHTT phenotypes in Drosophila. (A) Reducing Sir2 dose by half (Sir2+/2) protects photoreceptor
neurons from degeneration in flies challenged with mHttex1p Q93, but complete loss of Sir2 (Sir22/2) is deleterious (∗P , 0.05, ∗∗∗P , 0.005). (B) Animals het-
erozygous for Sir2 (+/2, black) show better climbing behavior than Htt-challenged animals with two doses of Sir2 (+/+, gray solid), while Sir2 2/2 animals
(dashed) have severely reduced climbing ability. (C) Selisistat rescues retinal neuron degeneration of mHttex1p Q93-challenged flies in a dose-dependent manner
(∗P , 0.05, ∗∗∗P , 0.005). (D) Treatment with 10 mM selisistat (black squares) tends to improve survival of mHtt-challenged animals with the greatest effect
seen in the 10–20 day survival rates (∗∗P , 0.01) compared with no drug controls (gray diamonds). Control males not expressing mHtt (gray circles) survive
much longer than mHtt-challenged females and are not affected by selisistat (not shown).
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selisistat exhibited positive effects in mammalian models of HD.
Rat pheochromocytoma cells (PC-12) expressing mHtt exon 1
fragments have been widely employed to study mHtt toxicity
and aggregation (24). PC-12 cells inducibly expressing an
exon 1 fragment of human Htt with an expanded polyglutamine
repeat present with aggregates, transcriptional changes and cyto-
toxicity upon transgene expression (24). In this model, induction
of mHtt expression results in a robust increase in toxicity
(measured as lactate dehydrogenase [LDH] release), which
was significantly reduced by treatment with selisistat at the
concentrations of 1 and 10 mM (Fig. 4A).
The neuroprotective activity of selisistat was also investigated
in a postmitotic, primary neuronal model. Infecting primary cul-
tures of rat striatal neurons with viral vectors expressing mHtt
fragments (25, 26) leads to decreased culture viability and aggre-
gates of Htt when the Htt transgene bears an expanded (mutant)
polyglutamine repeat (27). Therefore, striatal cultures infected
with lentiviruses expressing an N171 fragment of human Htt en-
coding either 18 or 82 glutamines were treated with selisistat to
investigate the neuroprotective activity of the compound. selisi-
stat was able to significantly protect cultured primary neurons
against cell loss (measured as NeuN counts) resulting from infec-
tion with a mHtt-expressing lentivirus (Fig. 4B).
Selisistat is protective in the R6/2 mouse model of HD
Finally, we sought evidence that chronic administration of seli-
sistat is protective in an in vivo mammalian model of HD. The
compound, which displays low clearance and complete oral bio-
availability as well as a 2:1 brain:plasma ratio in mice and
absence of overt toxicity in the mouse at dose levels up to
100 mg/kg (Table 1), was therefore tested in a transgenic
mouse model of HD. Among transgenic mouse models, the
R6/2 mouse (28) represents one of the most widely employed
and characterized in vivo models for preclinical studies and
has been the model of choice for a variety of pharmacological
preclinical trials (10,29,30). The R6/2 mouse expresses a
human exon 1 fragment encoding an expanded polyglutamine
repeat under control of the human Htt promoter and displays
rapid symptomatic onset and robust disease progression (31).
This model is characterized, among other phenotypes, by
decreased survival, loss of body weight, impaired motor activity,
striatal degeneration and the presence of Htt-positive aggregates
in the brain and other tissues.
To investigate the effects of selisistat, the compound was
administered to transgenic R6/2 mice beginning at 4.5 weeks
of age to death at doses of 5 and 20 mg/kg. The animals were sub-
jected to a battery of standardized, disease-relevant phenotypic
tests in a specialized contract research organization (Psycho-
Genics, Inc.). Treatment with selisistat resulted in a significant
increase of survival of mice receiving the 20 mg/kg dose with
a notable median lifespan increase of 3 weeks in comparison
with vehicle-treated animals (Fig. 5A). Significant improve-
ments were also observed when examining voluntary locomotor
activity (Open Field parameters, Fig. 5C and D). Namely, ad-
ministration of selisistat ameliorated the deficits of R6/2 mice
detected both in distance travelled in the center (Fig. 5C) and
the average velocity in the Open Field (Fig. 5D) for the 5 and
20 mg/kg regimens, respectively. Body weight (Fig. 5B),
rotarod performance and grip strength (data not shown) were
not significantly affected by treatment with selisistat.
The effects of selisistat on brain pathology were analyzed in
a satellite group of animals that was sacrificed at 12 weeks of
age (8 weeks of treatment). Ventricular volume and EM48
(Htt)-positive staining of aggregates were investigated as mea-
sures of striatal degeneration and Htt aggregate load, respectively.
HD-like pathological indicators in R6/2 mice mimicked those
seen in HD patients in the loss of striatal tissue with an associated
increase in ventricular volume and accumulation of EM48-
positive inclusions in the brain as seen in the top vehicle-treated
panels of Figure 6A and B. In mice treated with 5 mg/kg selisistat,
a statistically significant reduction of ventricular volume is
evident in comparison with vehicle-treated animals (Fig. 6A
and C). This improvement did not reach statistical significance
versus vehicle controls in the 20 mg/kg-treated animals due to a
somewhat larger variance, although a tendency towards reduced
volume was observed (Fig. 6A and C).
Brain slices were examined for the presence of inclusions of
EM48-positive aggregates in vehicle- and selisistat-treated
Figure 2. Target validation: dSir2 is the in vivo target of selisistat in
mHtt-challenged flies. (A) In mHTT flies challenged with Httex1p Q93 and
bearing the normal two doses of Sir2 (+/+), selisistat rescues photoreceptors,
while in the absence of Sir2 (2/2), the beneficial effects of selisistat on photo-
receptor neurodegeneration are eliminated. Retinal neuron survival that is typic-
ally improved by treatment with selisistat is abolished if the presumed target gene
is removed genetically (∗∗∗P, 0.005). (B) Elimination of the Sir2 target also
eliminates the effect of selisistat treatment on motor phenotype amelioration.
Treatment of mHtt-expressing animals harboring two doses of Sir2 (+/+)
with 10 mM selisistat (gray solid line) improved motor function compared with
untreated animals (gray dashed line). Genetic reduction of Sir2 (2/2) in
mHtt-challenged animals (black dashed line) decreased climbing ability and
was not rescued by treatment with 10 mM selisistat (black solid line). (∗∗P,
0.01 at 5 s).
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animals using automated image analysis. As evident in
Figure 6B and D, a significant decrease in the number of inclu-
sions was observed in selisistat-treated animals at the dose of
20 mg/kg and a trend toward reduction was also observed at
5 mg/kg.
Pharmacokinetic data (Table 1) indicate that the average
steady-state plasma levels in R6/2 mice at 5, 10 and 20 mg/kg/
day were 0.4, 1.5 and 3.2 mM, respectively, and that the brain ex-
posure was about 2-fold that in the systemic circulation, effect-
ively encompassing the drug concentrations used across the in
vitro experiments. Collectively, these data suggest that selisistat
can revert a number of mHtt-associated phenotypes when
applied to in vitro and in vivo Drosophila and mammalian
models of HD by targeting Sir2/SirT1 and inhibiting its activity.
DISCUSSION
Sir2 is a nuclear protein that primarily targets proteins involved
in transcription (32). The activity of Sir2, first described in yeast
as Silent Information Regulator, is central to the regulation of
chromatin packaging. The deacetylase activity of Sir2 tends to
silence transcription at target loci, many of which are involved
in metabolic functions. The sirtuins are unique among the
HDACs in their use of NAD+ as a cofactor. The requirement
for NAD+ provides a tight link between cellular metabolism
and transcriptional output. Sir2 removes acetyl groups from
lysine residues in histones (33, 34) and from other proteins in-
cluding several transcription factors such as members of the
FOXO family (35, 36), NFkB (37), PGC1a (38) and p53 (34).
Sir2 also represses the activity of the key chromatin-modifying
protein p300 (39), a histone acetyl transferase related to CBP,
which is also impaired in HD (6). Thus, the targets of Sir2/
SirT1 are primarily transcription-modifying proteins such as his-
tones, chromatin-modifying enzymes and transcription factors,
thus making it a potentially attractive target for affecting the
transcriptional dysregulation caused by pathogenic fragments
of mHtt. However, the genetic manipulation of HDACs and of
Sir2/SirT1 in particular in different preclinical models of HD,
either through overexpression, RNA inhibition or knockout of
Figure 3. Selisistat inhibits the deacetylation activity of both human SirT1 and Drosophila Sir2. (A andD) WB analysis of total cell lysates from HEK293 cells tran-
siently transfected with GCN5, p65 subunit and SirT1 (A) or Sir2 (D) (ratio 1: 0.5: 1). p65 acetylation was measured using a specific antibody against acetylated K310
and normalized to the total p65 content. The acetylation level in cells transfected with p65 and GCN5 only served as the control to evaluate the deacetylation activity of
SirT1 or Sir2. The acetylation level in cells transfected with p65, GCN5 and SirT1 or Sir2 and treated with DMSO served as the control to evaluate the effect of selisistat
treatment. The WBs shown are representative of three independent experiments. (B andE) Band intensity ratios normalized within each independent experiment (n ¼
3) show the extent of deacetylation by transfected SirT1 (B) or Sir2 (E). p65 deacetylation by SirT1 and Sir2, tested by applying the one-sample t-test versus the the-
oretical mean of 100, found the samples significantly different from respective controls (∗∗P , 0.01). (C andF) Band intensity ratios normalized within each experi-
ment (n ¼ 3) show the extent to which p65 acetylation is restored by the drug treatment in cells transfected with SirT1 (C) or Sir2 (F). One-way ANOVA analysis
followed by the Tukey–Kramer test for multiple comparisons found all concentrations of selisistat tested significantly different from DMSO control in SirT1-
transfected cells (∗∗∗P, 0.005) (C) and selisistat tested at 10 mM was significantly different from DMSO controls in Sir2-transfected cells (∗∗P, 0.01) (F).
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Sir2/SirT1 alleles (9,40–43) has led to differing views regarding
therapeutic strategies based on manipulation of Sir2/SirT1 activ-
ity. Our study and others support the notion that inhibition of Sir2
is protective in various neurodegenerative environments such as
AD mice (12), Ataxin-3-challenged Drosophila (11), oxida-
tively damaged cells (10), Drosophila models of HD (9) and
mHtt-challenged Drosophila, mammalian cells and mice chal-
lenged with mHtt exon 1 fragments (this study). Indeed, we
have previously shown that lowering (but, importantly, not elim-
inating) Sir2 gene dosage (through the generation of heterozy-
gous null alleles) or sirtuin inhibition provides substantial
amelioration in a Drosophila model of HD (9). Consistent with
this, complete lack of Sir2/SirT1 led to cell death and increased
toxicity in PC12 cells inducibly expressing mHtt exon 1. Other
genetic studies in mice suggest that increasing Sir2/SirT1
levels would provide relief through activation of the FOXO3A
and CREB pathways (41,42), although overexpression of Sir2
in Drosophila neurons either enhances the phenotype when
using an enhancer trap line that has a complex response
(9,40,44) or is lethal when using the elav-Gal4/UAS system
(44) (data not shown), making this an unlikely therapeutic
option. On the other hand, SirT1 directly deacetylates and
represses the activity of p300 (39), a histone acetyl transferase
related to CREB-binding protein which is also impaired in HD
(6), as well as Tip60, which promotes apoptosis (45), suggesting
that decreasing the levels of Sirt1/Sir2 might be relevant to path-
ology by increasing the activities of key histone-acetylating
enzymes, while overexpression may reduce the activity of key
enzymes such as CBP leading to reduced viability. Until recent-
ly, the paucity of potent and selective pharmacological modula-
tors (activators or inhibitors) of Sir2/SirT1 has prevented a
careful assessment of the therapeutic potential of pharmaco-
logical SirT1 modulation in preclinical disease models.
Access to a selective and effective Sir2/SirT1 inhibitor has
allowed a reassessment of the therapeutic potential of Sir2 inhib-
ition for HD using both new genetic and pharmacological tools.
We find that lowering Sir2 gene dosage using genetically targeted
knockouts improves neuronal survival, motor function and life-
span in a Drosophila model of HD. Importantly, these effects
can be phenocopied by a potent and selective SirT1 inhibitor (seli-
sistat) which possesses a profile suitable for clinical testing.
Through the use of combined genetic and pharmacological
approaches,wehave established that theendogenousHD-relevant
Figure 4.Pharmacological inhibition of SirT1 rescues mHTT-mediated toxicity in
mammaliancells. (A) InPC12cells induciblyexpressingahumanHTTexon1frag-
mentbearing 72 glutamine repeats, selisistat suppresses toxicity induced byexpres-
sion of the mHtt transgene. Data are represented as mean and SEM of normalized
data (induced control only—cited in the figure as ctrl ¼ 100%; uninduced ctrl ¼
0% not shown) (controls are DMSO-treated only). (∗P, 0.05, ∗∗P, 0.01 post-
ANOVA Tukey–Kramer test for multiple comparisons). (B) In primary rat striatal
cultures infected with lentiviral vectors expressing mutant (82Q) or wild type
(18Q), selisistat treatment abolished 82Q-HTT-induced neuronal loss in a
concentration-dependent manner. Data are displayed as mean and SEM (n ¼ 4).
(∗P, 0.05, ∗∗P, 0.01 by two-sample Student’s t-test for indicated comparisons).
Table 1. Pharmacokinetic parameters of selisistat in R6/2 mice (mean+SD,
n ¼ 3)
Dose (mg/kg) 5 mg/kg 10 mg/kg 20 mg/kg
Plasma Brain Plasma Plasma
Cmax (mM) 6.9+6.9 21.5+3.3 10.5+3.6 29.3+6.4
tmax (h) 0.3+0.1 1.0+0.0 0.8+0.4 0.5+0.0
AUC0 –t(last) (mM h) 9.9+4.5 71.1+9.1 35.4+10.4 77.5+9.7
t1/2,z (h) 2.7+2.3 2.8+0.4 1.4+0.5 0.9+0.2
Css,avg (mM) 0.4+0.2 3.0+0.4 1.5+0.4 3.2+0.4
Maximal plasma concentrations (Cmax) achieved at time tmax. AUC0 –t is the area
under the time versus plasma concentration curve at steady state and the Css,avg
indicates the average plasma concentration, i.e. the AUC0 –t divided by the
dosing interval, t (24 h). t1/2,z is the terminal plasma half-life. Brain versus
plasma was determined for 10 mg/kg only.
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target of selisistat in the fly is indeed Sir2, thus confirming that the
beneficial effects of reduced Sir2 in this model are not due to
alterations in non-HDAC SirT1 functions and providing proof
of target engagement for the compound. The demonstrated effi-
cacy of selisistat to inhibit mammalian SirT1 as well as rescue
neurons is promising, although the possibility of off-target
effects in mammalian systems cannot be strictly ruled out. As
Sir2 in turn can engage multiple downstream protein targets,
many of which have been identified as relevant to HD pathology
(e.g.histones,PGC1a,FOXO), inhibitionof Sir2can be thoughtof
as an intervention that is likely toengagemultipledisease-relevant
pathways that are modulated by Sir2 activity.
In this study, we have tested the effects of genetic and pharma-
cologic manipulation of Sir2/SirT1 activity in a robust, naturally
occurring disease-relevant model of HD (i.e. mHtt exon 1 ex-
pression). We find that selisistat displays cyto- and neuroprotec-
tive activity in both mitotic and postmitotic mammalian cellular
models of HD and that it displays positive effects on
disease-relevant phenotypes in both transgenic Drosophila and
R6/2 mice. Selisistat has completed clinical studies in healthy
volunteers to assess safety, tolerability and pharmacokinetics
as well as short-term studies (up to 12 weeks) in HD patients,
aimed at assessing safety, tolerability and pharmacodynamic
parameters, and satisfies all criteria to qualify as a candidate
for clinical efficacy studies in patients with HD.
MATERIALS AND METHODS
Drosophila crosses
To compare phenotypes of Htt-expressing animals in normal
versus a Sir2-altered background, flies that were elav-
Gal4[C155]; Sir2[17]/CyO were crossed to UAS-Httex1p Q93
homozygotes (line p463) (6). To produce the homozygous dele-
tionofSir2 inanHDbackground,flies thatwereelav-Gal4[C155];
Sir2[17]/CyO were crossed to UAS-Httex1p Q93 that contained
Figure 5. Effect of chronic administration of selisistat (5 and 20 mg/kg, PO, QD) on survival, body weight and behavioral parameters in mice. (A) R6/2 mice show
premature death. Improved survival was associated with selisistat administration (one-sided log-rank Mantel–Cox statistic: ∗P, 0.05). Pairwise comparison of in-
dividual dose groups with vehicle-treated mice indicated no effect in the 5 mg/kg group (P . 0.5) but significant increase in survival in the 20 mg/kg group (P , 0.05)
increasing median survival of 3 weeks. (B) The effect of chronic administration of selisistat (5 and 20 mg/kg, PO, QD) on body weights of the R6/2 mice from 4 to 25
weeks of age is depicted. R6/2 mice display lowered body weight compared with wild-type mice (data not shown). There was no statistically demonstrable effect of
treatment on body weight although statistical analysis of body weight could only be carried out to 19 weeks due to the need for multiple subjects in all groups to satisfy
conditions for ANOVA. (C andD) The effect of chronic administration of selisistat (5 and 20 mg/kg, PO, QD) in R6/2 mice on two different parameters of Open Field
performance, distance traveled in center (C) and average velocity (D). (C) A significant effect of treatment on distance traveled in the center of the open field was
observed with compound-treated mice. Individual comparison of drug-treated groups with the vehicle group across all ages revealed significant increases in
center locomotion in the 5 mg/kg group (∗∗P , 0.01). (D) A strong trend for treatment to increase velocity in the open field was detected in the 5 mg/kg group
(P ¼ 0.08), and individual group comparisons with vehicle revealed significant effects for the 20 mg/kg group (∗P , 0.05).
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Figure 6. Pharmacological inhibition of SirT1 prevents the enlargement of ventricular volume and lowers Htt inclusion load in R6/2 mice. Brain slices from
12-week-old mice were analyzed for ventricular volume and inclusions using image analysis software. (A) Representative photomicrographs of brains from R6/2
mice treated with vehicle or 5 or 20 mg/kg selisistat. Note the reduction of ventricular enlargement in treated animals. (C) Ventricular volume is reduced in R6/2
animals treated with selisistat compared with untreated R6/2 animals. Data are displayed as mean and SEM (∗P , 0.05 post-ANOVA Tukey–Kramer test for multiple
comparisons). (B andD) Pharmacological inhibition of SirT1 lowers aggregation load in R6/2 mice striata. Brain slices from 12-week-old mice were stained to detect
EM48-positive striatal inclusions. (B) Representative photomicrographs of striatal neurons from R6/2 mice treated with vehicle or 5 or 20 mg/kg selisistat. (D) Ana-
lysis of aggregate load in R6/2 mice striata in the different groups of animals expressed as percent of cells containing aggregates. Data are displayed as mean and SEM
(∗P , 0.05 post-ANOVA Tukey–Kramer test for multiple comparisons).
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Sir2[17] and a second chromosome marker. Crosses were per-
formed at 22.58C. After eclosion, adult flies were reared at 258C
on standard cornmeal molasses medium for genetic studies or
medium containing either 0.1% DMSO or the indicated concen-
tration of selisistat (0.1–10 mM) for pharmacological studies.
Fresh food was provided daily. Pseudopupil analysis was per-
formed at 7 days as described (6,21). For longevity experiments,
freshly enclosed virgins were aged in groups of 25–30 animals.
Longevity was determined by counting the number of surviving
animals to calculate percent survival, and flies were passed
every 2–3 days. Climbing of aged 7-day-old flies was performed
in polystyrene shell vials 9.5 cm in height with a diameter of
2.4 cm (Fisher Scientific, Pittsburgh, PA, USA). Vials were
placed in a holding box with the front and back open. A light
box was placed behind the vials to improve visibility of flies.
The flies were video recorded using an Exilim EX-FH20
camera with 40 f.p.s. The percentage of flies that climbed past
the midpoint of the vial was calculated as a function of time
after shakedown. Approximately 10–15 flies per vial were used
for the climbing assay. For overexpression of Sir2, the UAS-Sir2
line was generously provided by Dr. Karen Chang at USC.
PC-12 exon 1-expressing mutant/wild-type Htt cell lines
PC-12 7210 (exon 1 mutQ74) cells (PC12-Q74) stably expres-
sing a GFP-tagged-exon 1 fragment of the human HD gene
were obtained from Prof. Rubinsztein’s laboratory (24). The
tetracycline (Tet-on)-inducible mHTT construct comprises
nucleotides 1–297 of the human Htt sequence (NM_00211)
and includes a 74 CAG repeat expansion that, once expressed,
is toxic to the cells. Cells were seeded in a 96-well poly-D-lysine
(MW 70–150 kDa) (Sigma, MO, USA) precoated plate at a
density of 45K cells/100 ml medium/well in DMEM-containing
2% HS, 1% FBS, 100 mU/ml penicillin/streptomycin and 1%
glutamax, then grown for 24 h prior to the experiment in an incu-
bator at 378C, with 90% of relative humidity and 10% CO2 at-
mosphere. The day of the experiment, the same medium but
devoid of serum was added to the wells in order to obtain a
final dilution of the previous serum concentration to 1:3. For
transgene induction, the serum-free medium was complemented
with doxycycline (final concentration 1 mg/ml). Selisistat was
added (from a DMSO 10 mM stock solution) to obtain the final
concentrations described in the results, omitting its addition in
the controls that received DMSO only. The final concentration
of DMSO in all treatments and controls was 0.1%. At the 72 h
time point, cell death was assessed by measuring levels of
LDH released from cells in the medium using an LDH-Mix
Cytotoxicity Test Kit (Roche, Switzerland), absorbance was
measured at 490 nm (reading) and 720 nm (blank) with a spec-
trophotometer (Benchmark Plus, Bio-Rad, Hercules, CA, USA).
Preparation and culture of primary striatal neurons
Cultures were obtained after dissection of the brain ganglionic
eminence obtained from rat embryos at E15, after their
removal from a pregnant Sprague-Dawley rat (Janvier Labs), hu-
manely euthanized in accordance with applicable laws and
Animal Ethics approvals. Tissue was minced with forceps and
cells were mechanically dissociated in a solution of BSA
(1 mg/ml) in DMX medium by gently flushing the cell
suspension up and down with a tip-flamed Pasteur pipette. The
solution was allowed to settle until the remaining cell aggregates
could sediment to the bottom. The supernatant containing disso-
ciated cells was removed with the Pasteur pipette and transferred
to a new tube. A DMX/BSA solution was added to the remaining
cell aggregates, again dissociated mechanically by gently flush-
ing the cell suspension in the Pasteur pipette. The supernatant
was removed with the Pasteur pipette and transferred to the
new tube. A 5% BSA-PBS solution was added slowly to the
bottom of the tube containing the cell suspension. This step
allowed the formation of a BSA gradient, which removed any
debris from the cell suspension before plating. The cell suspen-
sion was centrifuged at 300g for 8 min at RT. Then, cells
were resuspended in Neurobasal medium containing B27,
100 mU/ml penicillin/streptomycin, L-glutamine (0.5 mM),
KCl (15 mM), plated in poly-L-lysine-coated multi-well plates
at a density of 150K cells/cm2 and placed in cell incubator set
at 378C with a 5% CO2 atmosphere.
Lentiviral infection of cultured striatal neurons
In vitro models of HD were realized using lentiviral vectors as
described (27). These models involve the lentiviral-mediated
overexpression of N-terminal 171 amino acid fragments of
wild-type Htt (with 18 glutamine repeats, 18Q) or mHtt (with
82 glutamine repeats, 82Q) in striatal neuronal cultures. For
lentiviral-mediated protein expression, cultures were infected
24 h after seeding. On Day 4, half of the medium was replaced
with the fresh medium supplemented with selisistat in 2× con-
centration. Treatments with compound were performed once a
week thereafter by adding fresh medium with compound at
1× concentration. The strong promoter constructs (high expres-
sion, 5–10 times endogenous) resulted in polyQ-dependent cell
death within 2–4 weeks in vitro, as assessed by reduced NeuN-
positivity and NeuN-positive cell numbers. Htt-N171-82Q- but
not Htt-N171-18Q-exposed cells also develop intracellular Htt
inclusions at 1–2 weeks (high expression) or 2–4 weeks (mod-
erate expression) in vitro. For the neurotoxicity assessment,
primary cultured striatal neurons were washed with PBS and
fixed with 4% paraformaldehyde in PBS (Fluka) for 15 min at
RT. After fixation, cells were washed three times with PBS
and blocked with 10% normal goat serum (NGS; Invitrogen)
in PBS supplemented with 0.1% Triton X-100 (Sigma). An anti-
NeuN/Fox-3 monoclonal antibody (Millipore) was diluted 1:500
in PBS with 5% NGS and 0.1% Triton X-100 and incubated with
the cells overnight at 48C. Cells were washed three times with
PBS and incubated for 1 h with goat-anti-mouse Cy3-conjugated
antibody (1:1000 dilution, Invitrogen) in PBS with 1% NGS, fol-
lowed by three washes with PBS. Images were acquired employ-
ing an automated high-throughput imaging system BD Pathway
855 Bioimager (Becton Dickinson) using a 4× objective. Image
processing and cell counting was performed using the public
domain software ImageJ. Thresholds for fluorescence intensity,
size and circularity of fluorescent objects were set to uniform
parameters for each experiment.
HEK293 cell transfection and treatments
HEK 293-T cells were grown in DMEM (Gibco, Invitrogen)
containing 10% FBS, 1% Penstrep (Gibco), 1% G-Max
Human Molecular Genetics, 2014, Vol. 23, No. 11 3003
(Gibco) at 378C and 10% CO2. 8 × 105 cells were seeded on
MW6 plates (Corning) and after 24 h, cells were transfected
with 2.5 mg of total plasmid DNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Plas-
mids expressing GCN5 (NM_021078.1), p65 (NM_021975.3),
human_SirT1 (NM_012238.4) were purchased from OriGene
Technologies, Rockville, MD, USA; plasmid expressing the
Drosophila gene Sir2 cDNA (LD07439) was ordered from
DGRC and cloned into a pcDNA vector. Four hours after trans-
fection, the Opti-MEM medium was removed and selisistat was
diluted to 0.1, 1 and 10 mM (DMSO 0.1%, v/v, as control) in the
culture medium and added to the cells. At 24 h posttransfection,
cells were collected and lysed in RIPA buffer (150 mM NaCl,
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris, pH 8.0) with protease and phosphatase inhibitors (Com-
plete EDTA-free protease inhibitor cocktail, Roche and Phos-
STOP inhibitor cocktail, Roche). Total lysates were clarified
by centrifugation at 3000g for 5 min and the protein amount
quantified by BCA (Pierce) according to the manufacturer’s
instructions.
Western blotting
Protein lysates (20 mg) were loaded on AnyKD TGX gels
(Bio-Rad) and transferred for 1 h at 100 V to PVDF membranes
(Amersham). Membranes were blocked in 3% NFM for 1 h,
washed with PBS containing 0.01% Tween-20 and incubated
with appropriate antibodies in 3% NFM. Primary antibodies
were used at the following concentrations: anti p65AcK310
at 1 mg/ml (Abcam), anti total p65 at 0.1 mg/ml (Abcam),
anti b-actin AC-74 clone, at 0.05 mg/ml (Sigma-Aldrich).
HRP-conjugated secondary antibodies (Bio-Rad) were diluted
1:20 000 in 3% NFM and incubated for 1 h at room temperature.
ECL Prime substrate (GE Healthcare) was used to develop




R6/2 transgenic mice carrying the N-terminal region of a mutant
human Htt gene (28) were bred by crossing ovarian transplanted
females (from R6/2 CBAB6J female donors, Jackson Laborator-
ies) with CBAxC57BL/6J F1 wild-type males. Genotype was
determined by real-time PCR of tail snips collected 10 days
of age. In mutant mice, the CAG repeat lengths were determined
by Genemapper software by Laragen Inc (28). Only mice with at
least 100 CAG repeats were included in the study. The average
CAG repeat length in this study was 108.9+ 0.5. Mice were
handled on 2 consecutive days (1 min each day) between 19
and 21 days of age. Animals were tail tattooed at 20–21 days
of age and weaned at 21–22 days of age. Mice from multiple
litters were used for each treatment group (equally divided
between genders). Mice were housed 4–5 mice/cage in Opti-
mice cages (Animal Care Systems, CO, USA) with wood shav-
ings, food and water; an enriched environment was created with
the addition of play tunnels, shredded paper and plastic bones.
Mice had free access to regular food and water and, in addition,
all mice received from weaning wet powdered food placed inside
a cup on the floor of the cage which was replaced fresh daily. All
manipulations and handling were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals, NRC 2011. The protocol was approved by
the Institutional Animal Care and Use Committee of Psycho-
Genics, Inc. (PHS OLAW animal welfare assurance number
A4471-01), an AAALAC International accredited Institution
(Unit #001213).
Body weight and survival
Mice were weighed twice a week and were examined daily
for survival analysis. Death was determined by lack of
heartbeat.
Behavioral tests
The following behavioral tests were performed during the light
phase of the diurnal cycle.
Open field
Activity chambers (Med Associates Inc, St Albans, VT, USA;
27 × 27 × 20.3 cm) were equipped with infrared beams. Mice
were placed in the center of the chamber and their behavior
was recorded for 30 min. Quantitative analysis was performed
on distant travelled (total and center), total rearing frequency
and velocity. Mice were tested at 3.5–4, 6, 8, 10 and 12 weeks
of age.
Rotarod
Mice were tested over 3 consecutive days at 3.5–4, 6, 8 and 10
weeks of age. Each daily session included a training trial of
6 min at 4 revolutions per minute (RPM) on the rotarod apparatus
(AccuScan, OH, USA). One hour later, the animals were tested
for three consecutive trials during which the speed accelerated
from 0 to 40 RPM over 360 s, with an intertrial interval at least
30 min. The latency to fall from the rod was recorded. Mice
remaining on the rod for .360 s were removed and their time
scored as 360 s. Data for the training trial were not included.
Grip strength
Mice were scruffed by the lower back and tail and lowered
towards the mesh grip piece on the gauge (Chatillion Force
Gauge, San Diego Instruments, San Diego, CA, USA) until the
animal grabbed on with both front paws. The animal was then
lowered toward the platform and gently pulled straight back
with consistent force until it released its grip. The forelimb
grip force was recorded on the strain gauge and averaged over
five trials. Mice were tested at 3.5–4, 6, 8, 10 and 12 weeks
of age.
Drug treatments
Treatments were started at 4.5 weeks of age after mice had been
tested at 3.5–4 weeks to establish baseline behavioral perform-
ance for all of the animals. Groups of 18 mice (9 per gender) were
assigned to each R6/2 group. Mice were balanced across experi-
mental groups by body weight, CAG repeats, date of birth and
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litter size before testing began. Mice were run in open field,
rotarod and grip strength at 3.5–4 weeks and treatment designa-
tions were rebalanced before drug treatments were started to
ensure that behavioral performance was initially similar
between treatment groups. Additional data used for rebalancing
the groups included rotarod fall time, total distance travelled
and total rearing frequency in the open field and grip strength.
Mice received daily (QD) oral gavage (PO; 10 ml/kg) of
selisistat (5 and 20 mg/kg) or its vehicle (0.5% hydroxyl-
propylmethylcellulose Methocel K4M Premium in sterile
water; 0.5% HPMC). Suspensions were prepared weekly and
aliquotted into amber vials (light sensitive) for daily dosing;
powdered drug was stored in a desiccator at 48C. Vehicle was
prepared bimonthly and stored at 48C. Each vial was vortexed
prior to dosing and contained a small stir bar and remained on
a stir plate during dosing. A satellite group of animals for phar-
macokinetic assessments were dosed from 3 to 10 weeks of
age with selisistat. Following the last dose, animals were termi-
nated and trunk blood samples were collected from three mice
per group at 0.25, 0.5, 1, 6 and 24 h postdose in heparin-coated
tubes kept on wet ice until centrifugation at 2700 RPM at
+48C. The supernatant was removed and plasma stored at
2808C until analysis using an LC–MS/MS method with a
lower limit of quantitation of 5 ng/ml. Pharmacokinetic param-
eter estimates were achieved using WinNonlin, v. 5.01.1,
Pharsight CA, USA.
Immunohistochemical analysis
A satellite group of animals (n ¼ 3/4) for morphological studies
was sacrificed at 12 weeks of age. The animals were perfused
transcardially with ice-cold paraformaldehyde solution (4% in
phosphate-buffer, pH 7.4). The brains were postfixed for 4 h
and cryoprotected in 18% sucrose solution. Brains were sec-
tioned in a cryostat into 30 mm-thick coronal sections and
placed in anti-freezer solution (phosphate-buffered saline con-
taining 30% ethylene glycol and 30% glycerol) and stored at
2208C until used for immunohistochemistry, according to the
following schedule:
Day 1: For detection of cholinergic neurons, the monoclonal
antibody EM48 raised against Htt protein (1:250 dilution)
(Chemicon International, Temecula, CA, USA) was used.
The sections were washed in PBS-Triton X-100 0.3%
(PBS-TX), and then incubated free-floating overnight at RT
with the primary antibody in PBS solutions containing
albumin 5 mg/ml, Triton X-100 0.3% and sodium azide 0.1%.
Day 2: After washing in PBS, sections were incubated in
biotinylated secondary antibody (1:1000 dilution, Vector
Laboratories, Burlingame, CA, USA) and subsequently
incubated in avidin–biotin–peroxidase complex (Vectastain,
Vector Laboratories, Burlingame, CA, USA, final dilution 1:
500) and stained using diaminobenzidine (DAB) (Vector La-
boratories, Burlingame, CA, USA) in the presence of NiCl.
DAB-stained slices were examined using an Olympus BX40
(Milan, Italy) microscope and photographed using a digital
camera (Olympus DP50).
Inclusions in EM48-positive cells and ventricular enlargements
were quantified in DAB-stained slices by transforming digitized
images to TIFF files and analyzing using Scion Image (Scion
Corporation, Frederic, MD, USA) for Windows. The gray back-
ground (non-specific staining) was calculated as a threshold,
automatically subtracted from each image and the area in
pixels above the set threshold was measured automatically
using SCION Image. Care was taken to maintain the same
gray threshold in the images from control and treated slices
from the same experiment and inclusions were scored by the
software without operator intervention. The area above the set
threshold was calculated in pixels.
Statistical analysis
Statistical analyses for the Drosophila pseudopupil assay and
climbing assay and analysis of data from primary striatal
neurons and p65 deacetylation by Sir2 and SirT1 were performed
using Student’s t-test. ∗P, 0.05, ∗∗P, 0.01; ∗∗∗P , 0.005.
Statistical analysis of data from in vitro experiments in PC-12
cells, band intensity ratios testing selisistat on Acp65K310
versus total p65 on SirT1/Sir2 and immunohistochemistry
ex vivo experiments were performed using one-way ANOVA
analysis.
In vivo studies in R6/2 mice: body weight, rotarod and open
field data were analyzed using repeated-measures analyses,
using mixed-effect models. All models were fitted using the
PROC MIXED procedure in SAS 9.1.3 (SAS Institute, Cary,
NC, USA). Treatment and age were the two independent
factors assessed. The within-subject correlation structure was
modeled through an autoregression: slight variations of those
models were tested and the best model based on the Akaike
and Bayesian Information Criteria was selected. Data from 4
weeks of age were used as baseline to compare against the behav-
ioral measurements taken between 6 and 12 weeks.
Survival data were analyzed with Kaplan–Meier survival
curves. Log-rank (Mantel–Cox) analysis was performed to
test effects on survival. When appropriate, post hoc paired
group analyses were conducted using the Tukey–Kramer test
to correct for multiple comparisons.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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